Analytical Data
-
Gene name
CYP3A5
- Application
-
Alternative Names
(CYPIIIA5)(Cytochrome P450-PCN3)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20815
-
Expression Region
1-502aa
-
Molecular Weight
61.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP3A5 is a member of the cytochrome P450 superfamily, which plays a crucial role in the metabolism of various drugs and endogenous compounds. It is known for its polymorphic expression in human populations, leading to significant interindividual variability in drug metabolism and responses. The CYP3A5 gene exhibits diverse alleles that influence protein expression levels, categorizing individuals as expressers, intermediate expressers, or non-expressers of CYP3A5. This variability can result in altered therapeutic outcomes and adverse effects for medications metabolized by this enzyme. Research on recombinant CYP3A5 protein is pivotal for understanding these metabolic pathways, enabling the development of personalized medicine strategies. By producing and characterizing recombinant CYP3A5 proteins, scientists can study the enzyme's structure-function relationships, enzymatic activity, and inhibitor interactions. Additionally, this research assists in elucidating the metabolic pathways of drugs, particularly those used in pharmacotherapy, including tacrolimus and warfarin, among others. The insights gained from CYP3A5 recombinant protein studies are essential for optimizing drug dosing regimens and improving patient outcomes, thereby highlighting the importance of pharmacogenomics in modern healthcare.
